The Biological Functions and Clinical Applications of Integrins in Cancers

Integrins are the adhesion molecules and receptors of extracellular matrix (ECM). They mediate the interactions between cells-cells and cells-ECM. The crosstalk between cancer cells and their microenvironment triggers a variety of critical signaling cues and promotes the malignant phenotype of cance...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 11; p. 579068
Main Authors Su, Chao-yue, Li, Jing-quan, Zhang, Ling-ling, Wang, Hui, Wang, Feng-hua, Tao, Yi-wen, Wang, Yu-qing, Guo, Qiao-ru, Li, Jia-jun, Liu, Yun, Yan, Yan-yan, Zhang, Jian-ye
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 11.09.2020
Subjects
cancer metastasis
drug resistance
extracellular matrix
integrins
Pharmacology
stemness
therapeutic targeting
Online AccessGet full text

Cover

More Information
Summary:Integrins are the adhesion molecules and receptors of extracellular matrix (ECM). They mediate the interactions between cells-cells and cells-ECM. The crosstalk between cancer cells and their microenvironment triggers a variety of critical signaling cues and promotes the malignant phenotype of cancer. As a type of transmembrane protein, integrin-mediated cell adhesion is essential in regulating various biological functions of cancer cells. Recent evidence has shown that integrins present on tumor cells or tumor-associated stromal cells are involved in ECM remodeling, and as mechanotransducers sensing changes in the biophysical properties of the ECM, which contribute to cancer metastasis, stemness and drug resistance. In this review, we outline the mechanism of integrin-mediated effects on biological changes of cancers and highlight the current status of clinical treatments by targeting integrins.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Xiaoping Lin, Sun Yat-sen University Cancer Center (SYSUCC), China
Reviewed by: Zhi Shi, Jinan University, China; Longyang Liu, Southern Medical University, China
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2020.579068